Phase I study of conformal radiotherapy and concurrent full-dose gemcitabine with erlotinib for unresected pancreatic cancer. [electronic resource]
Producer: 20120316Description: e187-92 p. digitalISSN:- 1879-355X
- Aged
- Aged, 80 and over
- Antimetabolites, Antineoplastic -- administration & dosage
- Deoxycytidine -- administration & dosage
- Drug Administration Schedule
- Drug Therapy, Combination -- methods
- Erlotinib Hydrochloride
- Female
- Humans
- Infections -- etiology
- Male
- Maximum Tolerated Dose
- Middle Aged
- Nausea -- etiology
- Pancreatic Neoplasms -- drug therapy
- Quinazolines -- administration & dosage
- Radiation-Sensitizing Agents -- administration & dosage
- Radiotherapy Dosage
- Radiotherapy, Conformal -- adverse effects
- Time Factors
- Tumor Burden -- radiation effects
- Vomiting -- etiology
- Gemcitabine
No physical items for this record
Publication Type: Clinical Trial, Phase I; Journal Article
There are no comments on this title.
Log in to your account to post a comment.